Status:
COMPLETED
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
GIST, Malignant
Liver Metastases
Eligibility:
All Genders
18-75 years
Brief Summary
The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinib(IM) and IM alone in patients suffering from GIST liver metastases. The main ...
Detailed Description
Gastrointestinal stromal tumors (GISTs) represent the most prevalent type of mesenchymal tumor within the gastrointestinal tract, and the liver is the most common site of metastasis from GIST. Imatini...
Eligibility Criteria
Inclusion
- Pathological evidence of GIST of primary tumors
- Liver metastases evidenced by biopsy or radiological findings
- Sufficient liver, hematologic, and renal function, coupled with an Eastern Cooperative Oncology Group performance status score ranging from 0 to 1
Exclusion
- IM was not used during treatment
- Liver metastases appeared on second-line or later subsequent lines of TKI
- Combined with other malignant tumors
- Failure to follow up
Key Trial Info
Start Date :
January 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
238 Patients enrolled
Trial Details
Trial ID
NCT06038552
Start Date
January 1 2002
End Date
May 1 2023
Last Update
February 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China